CD40 Ligand antibody (PE-Cy5)

Catalog No. ABIN2658922

The Mouse Monoclonal anti-CD40 Ligand antibody has been validated for BCA. It is suitable to detect CD40 Ligand in samples from Human.

Quick Overview for CD40 Ligand antibody (PE-Cy5) (ABIN2658922)

Target: CD40 Ligand (CD40LG)

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD40 Ligand antibody is conjugated to PE-Cy5

Application: Biochemical Assay (BCA)

Clone: 24-31

Product Details anti-CD40 Ligand Antibody (PE-Cy5)

Cross-Reactivity: Cynomolgus, Rhesus Monkey

Purification: The antibody was purified by affinity chromatography, and conjugated with PE/Cy5 under optimal conditions. The solution is free of unconjugated PE/Cy5 and unconjugated antibody.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CD40 Ligand

Target: CD40 Ligand (CD40LG)

Alternative Name: CD154

Background: CD154 (CD40 ligand) is also known as CD40L, gp39, TRAP and T-BAM. CD40 ligand is a 32-39 kD type II transmembrane glycoprotein. It is a member of the TNF superfamily and is expressed on activated T cells. It has been reported to be important for B cell costimulation following binding of its receptor, CD40. Additionally, binding of CD40L to CD40 on B cells promotes the secretion of immunoglobulin and Ig isotype switching. CD40L is also involved in the regulation of cytokine production by T cells.

Pathways: NF-kappaB Signaling, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints